Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to -$2.6 million.

  • Corvus Pharmaceuticals' Cash from Investing Activities rose 3269.92% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.8 million, marking a year-over-year decrease of 438.47%. This contributed to the annual value of -$27.5 million for FY2024, which is 27684.83% down from last year.
  • Latest data reveals that Corvus Pharmaceuticals reported Cash from Investing Activities of -$2.6 million as of Q3 2025, which was up 3269.92% from -$20.3 million recorded in Q2 2025.
  • Corvus Pharmaceuticals' 5-year Cash from Investing Activities high stood at $17.5 million for Q3 2023, and its period low was -$25.6 million during Q1 2022.
  • Over the past 4 years, Corvus Pharmaceuticals' median Cash from Investing Activities value was -$2.6 million (recorded in 2025), while the average stood at -$3.6 million.
  • Per our database at Business Quant, Corvus Pharmaceuticals' Cash from Investing Activities tumbled by 30811.38% in 2024 and then soared by 6071428.57% in 2025.
  • Corvus Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$3.9 million in 2022, then surged by 40.29% to -$2.3 million in 2023, then tumbled by 162.42% to -$6.1 million in 2024, then soared by 56.96% to -$2.6 million in 2025.
  • Its Cash from Investing Activities stands at -$2.6 million for Q3 2025, versus -$20.3 million for Q2 2025 and $4.2 million for Q1 2025.